Group Leader, Antibody-Oligonucleotide Conjugates (Extrahepatic Delivery)

The RNA Society; Indiana (PA); On-site; USD 141,000 - 204,000; Full time

Job summary

NATi seeks a Group Leader to build and guide an interdisciplinary team focused on antibody-oligonucleotide conjugates (AOCs) for extrahepatic delivery. You will own scientific strategy, drive development, and partner with chemistry, DMPK, and bioanalytics to deliver asset programs.

Responsibilities include defining design principles for tissue targeting, leading antibody discovery and bioconjugation efforts, establishing platform capabilities, and delivering robust in vitro and in vivo readouts.

Qualifications

• PhD-level degree in a relevant field.
• +8+ years or more experience in pharma/biotech with AOC/ADC experience.
• Proven leadership with program ownership and IP activity.

Responsibilities

• Define AOC design principles for extrahepatic delivery and tissue targeting.
• Lead antibody discovery, engineering and developability efforts.
• Own the bioconjugation strategy and platform development.
• Establish analytical and developability workflows (DAR, purity, stability).
• Coordinate with DMPK, Bioanalytics and CMC for scale-up readiness.

Skills

Protein engineering

Antibody discovery

Bioconjugation chemistry

Cross-functional leadership

Strategic planning

Education

Doctorate in Protein Engineering or related field

Tools

LC-MS

SEC

CE-SDS

HIC

UV/fluorescence

Ion exchange

Job description

Position Overview

We seek a highly innovative and results-driven Group Leader to build and lead an interdisciplinary team developing antibody-oligonucleotide conjugates (AOCs) for extrahepatic delivery. This role will integrate antibody discovery and engineering with linker chemistry, oligonucleotide conjugation, and fit-for-purpose bioanalytical and functional validation to enable asset generation beyond established hepatic indications. The successful candidate will own the scientific strategy and execution for the AOC platform, build an efficient group, establish platform capabilities (e.g., automation, conjugation, analytics, in vitro assays), and partner closely with oligonucleotide chemistry, DMPK, and bioanalytics teams.

Key Responsibilities

• Scientific Leadership & Program Ownership
• Define AOC design principles for extrahepatic delivery (i.e., target selection, tissue/cell specificity, internalization, trafficking, endosomal escape strategies, payload selection, etc.).
• Drive program strategy, milestones, and decision-making frameworks (e.g., experimental plan, MOA validation, translation plan, developability risk).
• Lead multi-disciplinary project teams and represent AOC programs in governance forums and senior leadership reviews.
• Antibody Discovery, Engineering & Developability
• Guide antigen and epitope strategy for extrahepatic tissue targeting (e.g., muscle, adipose tissue, immune cells).
• Oversee generation, screening, and prioritization of antibodies via different display technologies (e.g., phage/yeast display, hybridoma, or computational design) using a balanced combination of internal capability and external CROs
• Engineer antibodies for:
• Affinity/avidity optimization, cross-reactivity, and species selection
• Internalization/trafficking (recycling vs. degradative pathways)
• Biophysical stability (aggregation, viscosity), PTMs, and manufacturability
• Establish developability workflows (e.g., expression, purification, stability, aggregation, poly-specificity, immunogenicity risk screening) using a balanced combination of internal capability and external CROs
• Linker Chemistry & Oligo Conjugation Platform
• Own the bioconjugation strategy (site‑specific vs. stochastic; cysteine/lysine conjugation, enzymatic conjugation, non‑natural amino acids, glycan remodeling, click chemistry, etc.).
• Partner with oligo chemists to define oligo formats (siRNA, ASO, splice‑switching oligos, etc.), chemical modifications, and conjugation handles.
• Design and optimize linkers for:
• Stability in systemic circulation
• Controlled release (if/as applicable)
• Compatibility with antibody and oligo chemistry
• Scalability and CMC readiness
• Establish analytical methods to quantify DAR, positional heterogeneity, purity, and stability (e.g., LC‑MS, SEC, CE‑SDS, HIC, UV/fluorescence, ion exchange, oligo integrity assays) plus hands‑on experience with multiscale purification and analytical characterization instruments.
• Functional Validation Readouts
• Develop and oversee in vitro assays to confirm:
• Binding and internalization (e.g., flow cytometry, microscopy, ligand competition)
• Intracellular trafficking/endosomal escape proxies
• Oligo activity (e.g., knockdown/splice modulation/qPCR/NGS readouts)
• Drive in vivo PK/PD and biodistribution studies in relevant models in close partnership with pharmacology team
• Cross‑Functional Partnering
• Collaborate with DMPK to establish AOC‑specific ADME understanding (e.g., deconjugation, metabolite profiling, clearance mechanisms)
• Partner with Bioanalytics to set up assays for intact conjugate, total antibody, free oligo, and catabolites.
• Work with CMC/process development for scale‑up readiness, control strategy, and quality attributes (CQAs) relevant to AOCs
• People Leadership & Capability Building
• Recruit, mentor, and lead a team across protein science, conjugation chemistry, and biology
• Establish best practices for experimental design, documentation, and reproducibility; cultivate a culture of scientific excellence with a sense of urgency
• Identify and manage CRO partnerships to accelerate program timelines; Lead strategic collaborations as needed
• Lead innovation in AOC engineering to expand NATi’s intellectual property (IP) portfolio.
• Coordinate technical documentation and patent filings in collaboration with legal and scientific teams.
• Prepare appropriate summary reports and presentations to update NATi leadership and stakeholders.

Qualifications & Experience

• A doctorate degree in Protein Engineering, Chemical Biology, Bioconjugation Chemistry, Organic/Medicinal Chemistry, or a related field.
• A minimum of +8 (Sr. Scientist) or +12 (Principal Scientist) years of relevant experience in pharmaceutical or biotech organizations.
• Demonstrated track record in antibody discovery/engineering and bioconjugation with clear ownership of programs advancing toward development.
• Hands‑on experience with conjugation design, linker selection, and analytical characterization of conjugates (AOCs, ADCs, or related conjugate modalities).
• Proven ability to lead cross‑functional teams, set strategy, and deliver milestones in a matrix environment.
• Demonstrated innovation through IP, publications, IND filings, or other public disclosures.
• A dependable contributor to cross‑functional teams who embraces a collaborative culture while demonstrating the autonomy/initiative to deliver on assigned scientific and operational responsibilities.
• Excellent organizational, interpersonal, and verbal/written communication skills.
• This position is based in Singapore. Successful candidates must be willing to relocate to Singapore.

Global Recruitment & Notes

NATi is conducting a global search for top-tier talent in RNA therapeutics. We welcome applications from leading pharmaceuticals scientists and biotech innovators worldwide. This role provides a highly competitive compensation package aligned with global industry standards, including attractive benefits and long-term career growth opportunities within Singapore’s thriving biomedical innovation ecosystem. Join us in shaping the future of RNA‑based medicines and establishing Singapore as a world‑class hub for nucleic acid therapeutics.